Pilot study of fixed-infusion rate gemcitabine with Cisplatin and dexamethasone in patients with relapsed or refractory lymphoma

Clinical Lymphoma
Christos EmmanouilidesPeter Rosen

Abstract

Management of patients with multiple-relapsed lymphoma meets with little success. The optimal use of available drugs in this situation is often unknown. Gemcitabine has documented efficacy in this setting. Pharmacodynamic data suggest that the optimal use may involve a fixed-rate infusion and coadministration with platinum compounds. In this study we explored the use of gemcitabine starting at a dose of 800 mg/m(2) administered at a fixed infusion rate of 10 mg/m(2) per minute with cisplatin 35 mg/m(2) intravenously, both given on day 1, and dexamethasone 20 mg daily for 4 days; the treatment was given every 2 weeks (days 1 and 15 of a 28-day cycle) for the treatment of relapsed Hodgkin's and non-Hodgkin's lymphoma. Dose escalation of gemcitabine was allowed according to phase I criteria. Twenty-two patients with a median of 4 prior treatments were enrolled (Hodgkin's lymphoma, n = 7; B-cell non-Hodgkin's lymphoma, n = 9; T-cell non-Hodgkin's lymphoma, n = 6). Ten patients had relapsed after prior autologous transplantation. Grade 4 thrombocytopenia and neutropenia were the dose-limiting toxicities and occurred in 9 patients (41%) and 4 patients (18%), respectively. Initial dose escalation of gemcitabine was not possible. Respo...Continue Reading

References

May 1, 2001·British Journal of Haematology·S SallahN P Nguyen

❮ Previous
Next ❯

Citations

Oct 26, 2013·Annals of Hematology·Eliza A HawkesIan Chau
Oct 1, 2008·Current Hematologic Malignancy Reports·Hilary M O'Leary, Kerry J Savage
Aug 19, 2008·Current Oncology Reports·Hilary M O'Leary, Kerry J Savage
Nov 6, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·P L ZinzaniM Baccarani
Jan 9, 2007·Journal of the American Animal Hospital Association·Chelsea B GreenbergMichael D Lucroy
Apr 13, 2011·British Journal of Haematology·Claire E DeardenUNKNOWN British Committee for Standards in Haematology
Sep 10, 2014·Cancer Treatment Reviews·Bertrand CoiffierPier Luigi Zinzani
Mar 28, 2017·Hematology/oncology Clinics of North America·Dai Chihara, Michelle A Fanale
Jun 9, 2014·Annals of Hematology·Cinzia PellegriniPier Luigi Zinzani
Mar 23, 2011·Expert Review of Anticancer Therapy·Rebecca A Howman, H Miles Prince
Nov 1, 2006·Annals of Oncology : Official Journal of the European Society for Medical Oncology·F MorschhauserC Dumontet

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

B-Cell Lymphoma

B-cell lymphomas include lymphomas that affect B cells. This subtype of cancer accounts for over 80% of non-Hodgkin lymphomas in the US. Here is the latest research.